The route to approval in the US has been a bit bumpier but Sanofi is celebrating this morning (3 July) as the European Commission has made its megablockbuster Dupixent the first-ever approved targeted therapy for chronic obstructive pulmonary disease (COPD).
Sanofi Secures World First Approval For Dupixent In COPD With EU Nod
The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.
More from Respiratory
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.